{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:40:13Z","timestamp":1788565213687,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000646","name":"Japan Society for the Promotion of Science London","doi-asserted-by":"publisher","award":["JP20K18327"],"award-info":[{"award-number":["JP20K18327"]}],"id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018884","name":"Aichi Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Auris Nasus Larynx"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.anl.2025.12.004","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T21:39:35Z","timestamp":1765402775000},"page":"27-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["C-C chemokine receptor 4 is a candidate for regulatory T-cell-depletion immunotherapy in differentiated thyroid cancer"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2576-4627","authenticated-orcid":false,"given":"Rui","family":"Sano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromu","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Inukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunpei","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taishi","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Satou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyonori","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuzo","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anl.2025.12.004_bib0001","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1056\/NEJMra1501993","article-title":"Biologic and clinical perspectives on thyroid cancer","volume":"375","author":"Fagin","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anl.2025.12.004_bib0002","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1001\/archoto.2010.55","article-title":"Thyroid cancer survival in the United States: observational data from 1973 to 2005","volume":"136","author":"Davies","year":"2010","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.anl.2025.12.004_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"10.1016\/j.anl.2025.12.004_bib0004","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1089\/thy.1998.8.715","article-title":"Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches","volume":"8","author":"Ain","year":"1998","journal-title":"Thyroid"},{"key":"10.1016\/j.anl.2025.12.004_bib0005","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.anl.2025.12.004_bib0006","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anl.2025.12.004_bib0007","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1002\/cncr.34493","article-title":"Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: updated results from the phase 3 COSMIC-311 trial","volume":"128","author":"Brose","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.anl.2025.12.004_bib0008","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/jjco\/hyv201","article-title":"Current status of immunotherapy","volume":"46","author":"Suzuki","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.anl.2025.12.004_bib0009","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1200\/JCO.19.02727","article-title":"PD-1 blockade in anaplastic thyroid carcinoma","volume":"38","author":"Capdevila","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anl.2025.12.004_bib0010","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1089\/thy.2020.0322","article-title":"Combination of Lenvatinib and Pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma","volume":"31","author":"Dierks","year":"2021","journal-title":"Thyroid"},{"key":"10.1016\/j.anl.2025.12.004_bib0011","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12885-019-5380-3","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer","volume":"19","author":"Mehnert","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.anl.2025.12.004_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.929091","article-title":"What is the status of immunotherapy in thyroid neoplasms?","volume":"13","author":"Garcia-Alvarez","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.anl.2025.12.004_bib0013","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in the cancer genome atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.anl.2025.12.004_bib0014","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.anl.2025.12.004_bib0015","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.immuni.2019.01.020","article-title":"Human FOXP3+ regulatory T cell heterogeneity and function in autoimmunity and cancer","volume":"50","author":"Wing","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.anl.2025.12.004_bib0016","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","article-title":"Regulatory T cells and Human disease","volume":"38","author":"Sakaguchi","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.anl.2025.12.004_bib0017","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","article-title":"Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy","volume":"41","author":"Tay","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.anl.2025.12.004_bib0018","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1210\/jc.2009-2564","article-title":"Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer","volume":"95","author":"French","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.anl.2025.12.004_bib0019","doi-asserted-by":"crossref","first-page":"E934","DOI":"10.1210\/jc.2011-3428","article-title":"Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer","volume":"97","author":"French","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.anl.2025.12.004_bib0020","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1158\/2326-6066.CIR-14-0201","article-title":"PD-1+tim-3+ CD8+ T lymphocytes display varied degrees of functional exhaustion in patients with regionally metastatic differentiated thyroid cancer","volume":"3","author":"Severson","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.anl.2025.12.004_bib0021","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1210\/jc.2015-4227","article-title":"Tumor-infiltrating T cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer","volume":"101","author":"Bastman","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.anl.2025.12.004_bib0022","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.immuni.2009.03.019","article-title":"Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor","volume":"30","author":"Miyara","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.anl.2025.12.004_bib0023","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ijc.25429","article-title":"Regulatory T cells in tumor immunity","volume":"127","author":"Nishikawa","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.anl.2025.12.004_bib0024","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1111\/cas.14422","article-title":"Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers","volume":"111","author":"Suzuki","year":"2020","journal-title":"Cancer Sci"},{"key":"10.1016\/j.anl.2025.12.004_bib0025","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/ijc.30475","article-title":"ICOS+ Foxp3+ TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with Helicobacter pylori","volume":"140","author":"Nagase","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.anl.2025.12.004_bib0026","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nm.4086","article-title":"Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers","volume":"22","author":"Saito","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.anl.2025.12.004_bib0027","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/j.1365-2133.2010.10199.x","article-title":"Perturbations of both nonregulatory and regulatory FOXP3+ T cells in patients with malignant melanoma","volume":"164","author":"Fujii","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anl.2025.12.004_bib0028","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/JTO.0000000000000364","article-title":"Increase in activated treg in TIL in lung cancer and in vitro depletion of treg by ADCC using an antihuman CCR4 mAb (KM2760)","volume":"10","author":"Kurose","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.anl.2025.12.004_bib0029","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s12094-014-1222-6","article-title":"Analysis of regulatory T cells frequency in peripheral blood and tumor tissues in papillary thyroid carcinoma with and without Hashimoto's thyroiditis","volume":"17","author":"Liu","year":"2015","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.anl.2025.12.004_bib0030","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1210\/jc.2011-1838","article-title":"Phenotypical analysis of lymphocytes with suppressive and regulatory properties (Tregs) and NK cells in the papillary carcinoma of thyroid","volume":"97","author":"Gogali","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.anl.2025.12.004_bib0031","first-page":"3128","article-title":"Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody","volume":"59","author":"Onizuka","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.anl.2025.12.004_bib0032","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1073\/pnas.1812186116","article-title":"Differential control of human treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody","volume":"116","author":"Ha","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.anl.2025.12.004_bib0033","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1158\/1078-0432.CCR-15-0357","article-title":"Phase Ia study of FoxP3+ CD4 treg depletion by infusion of a humanized anti-CCR4 antibody, KW-0761, in cancer patients","volume":"21","author":"Kurose","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anl.2025.12.004_bib0034","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2114282119","article-title":"CCR8-targeted specific depletion of clonally expanded treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory","volume":"119","author":"Kidani","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.anl.2025.12.004_bib0035","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1158\/2326-6066.CIR-20-0034","article-title":"An antibody targeting ICOS increases intratumoral cytotoxic to regulatory T-cell ratio and induces tumor regression","volume":"8","author":"Sainson","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.anl.2025.12.004_bib0036","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1038\/s41467-021-22885-8","article-title":"Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas","volume":"12","author":"Amoozgar","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.anl.2025.12.004_bib0037","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000957","article-title":"TIGIT in cancer immunotherapy","volume":"8","author":"Chauvin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.anl.2025.12.004_bib0038","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.3390\/biomedicines11071878","article-title":"LAG-3 inhibitors: novel immune checkpoint inhibitors changing the landscape of immunotherapy","volume":"11","author":"Ibrahim","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.anl.2025.12.004_bib0039","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anl.2025.12.004_bib0040","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010634","article-title":"Phase I study on neoadjuvant combination immunotherapy with mogamulizumab and nivolumab for solid tumors","volume":"13","author":"Jinushi","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.anl.2025.12.004_bib0041","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1158\/0008-5472.CAN-12-2325","article-title":"VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer","volume":"73","author":"Terme","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.anl.2025.12.004_bib0042","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1158\/1078-0432.CCR-23-3417","article-title":"Combination targeted therapy with Pembrolizumab and Lenvatinib in progressive, radioiodine-refractory differentiated thyroid cancers","volume":"30","author":"French","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anl.2025.12.004_bib0043","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1089\/thy.2010.0429","article-title":"Thyroid hormones as modulators of immune activities at the cellular level","volume":"21","author":"De Vito","year":"2011","journal-title":"Thyroid"},{"key":"10.1016\/j.anl.2025.12.004_bib0044","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1210\/clinem\/dgab191","article-title":"High levels of thyroid hormone impair regulatory T cell function via reduced PD-1 expression","volume":"106","author":"Zhong","year":"2021","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Auris Nasus Larynx"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814625001798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814625001798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T20:28:22Z","timestamp":1776889702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0385814625001798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0385814625001798"],"URL":"https:\/\/doi.org\/10.1016\/j.anl.2025.12.004","relation":{},"ISSN":["0385-8146"],"issn-type":[{"value":"0385-8146","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"C-C chemokine receptor 4 is a candidate for regulatory T-cell-depletion immunotherapy in differentiated thyroid cancer","name":"articletitle","label":"Article Title"},{"value":"Auris Nasus Larynx","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anl.2025.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Otorhinolaryngology-Head and Neck Surgery, Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}